Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · see citing works

The origin and evolution of mutations in acute myeloid leukemia

Welch, J. S., Ley, T. J., Link, D. C., Miller, C. A., Larson, D. E., Koboldt, D. C., Wartman, L. D., Lamprecht, T. L., Liu, F., Xia, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.023 · Cited by 1,575 · see citing works

Epigenetic protein families: a new frontier for drug discovery

Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327 · see citing works

Interplay between the Cancer Genome and Epigenome

Shen, H., & Laird, P. W. (2013) · Cell · doi:10.1016/j.cell.2013.03.008 · Cited by 912 · see citing works

Regulation of LSD1 Histone Demethylase Activity by Its Associated Factors

Shi, Y.-J., Matson, C., Lan, F., Iwase, S., Baba, T., & Shi, Y. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.08.027 · Cited by 891 · see citing works

Molecular mechanisms and potential functions of histone demethylases

Kooistra, S. M., & Helin, K. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3327 · Cited by 882 · see citing works

The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation

Wang, J., Hevi, S., Kurash, J. K., Lei, H., Gay, F., Bajko, J., Su, H., Sun, W., Chang, H., Xu, G., et al. (2008) · Nature Genetics · doi:10.1038/ng.268 · Cited by 827 · see citing works

p53 is regulated by the lysine demethylase LSD1

Huang, J. L., Sengupta, R., Espejo, A. B., Lee, M. G., Dorsey, J. A., Richter, M., Opravil, S., Shiekhattar, R., Bedford, M. T., Jenuwein, T., et al. (2007) · Nature · doi:10.1038/nature06092 · Cited by 820 · see citing works

Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia

Schenk, T., Chen, W. C., Göllner, S., Howell, L., Jin, L., Hebestreit, K., Klein, H.-U., Popescu, A. C., Burnett, A., Mills, K., et al. (2012) · Nature Medicine · doi:10.1038/nm.2661 · Cited by 672 · see citing works

Enhancer decommissioning by LSD1 during embryonic stem cell differentiation

Whyte, W. A., Bilodeau, S., Orlando, D. A., Hoke, H. A., Frampton, G. M., Foster, C. T., Cowley, S. M., & Young, R. A. (2012) · Nature · doi:10.1038/nature10805 · Cited by 602 · see citing works

The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells

Harris, W. J., Huang, X., Lynch, J. T., Spencer, G. J., Hitchin, J. R., Li, Y., Ciceri, F., Blaser, J. G., Greystoke, B. F., Jordan, A. M., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.014 · Cited by 566 · see citing works

Lysine-Specific Demethylase 1 Is Strongly Expressed in Poorly Differentiated Neuroblastoma: Implications for Therapy

Schulte, J. H., Lim, S., Schramm, A. R., Friedrichs, N., Köster, J., Versteeg, R., Øra, I., Pajtler, K. W., Klein‐Hitpaß, L., Kuhfittig-Kulle, S., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1735 · Cited by 447 · see citing works

Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells

Fiskus, W. C., Wang, Y., Sreekumar, A., Buckley, K. M., Shi, H., Jillella, A., Üstün, C., Rao, R., Fernandez, P., Chen, J., et al. (2009) · Blood · doi:10.1182/blood-2009-03-213496 · Cited by 357 · see citing works

LSD1 regulates the balance between self-renewal and differentiation in human embryonic stem cells

Adamo, A., Sesé, B., Boué, S., Castaño, J., Paramonov, I., Barrero, M. J., & Belmonte, J. C. I. (2011) · Nature Cell Biology · doi:10.1038/ncb2246 · Cited by 342 · see citing works

Structural Basis for CoREST-Dependent Demethylation of Nucleosomes by the Human LSD1 Histone Demethylase

Yang, M., Gocke, C. B., Luo, X., Borek, D., Tomchick, D. R., Machius, M., Otwinowski, Z., & Yu, H. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.07.012 · Cited by 331 · see citing works

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3

George, P., Bali, P., Annavarapu, S., Scuto, A., Fiskus, W. C., Guo, F., Sigua, C. A., Sondarva, G. V., Moscinski, L. C., Atadja, P. W., et al. (2004) · Blood · doi:10.1182/blood-2004-09-3413 · Cited by 327 · see citing works

Over-Expression of LSD1 Promotes Proliferation, Migration and Invasion in Non-Small Cell Lung Cancer

Lv, T., Yuan, D., Miao, X., Lv, Y., Zhan, P., Shen, X., & Song, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035065 · Cited by 275 · see citing works

Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia

Abdel-Wahab, O. I., & Levine, R. L. (2013) · Blood · doi:10.1182/blood-2013-01-451781 · Cited by 248 · see citing works

Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice

Vassiliou, G. S., Cooper, J. L., Rad, R., Li, J., Rice, S. V., Uren, A. G., Rad, L., Ellis, P., Andrews, R., Banerjee, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.796 · Cited by 233 · see citing works

Novel Histone Demethylase LSD1 Inhibitors Selectively Target Cancer Cells with Pluripotent Stem Cell Properties

Wang, J., Lu, F., Ren, Q., Sun, H., Xu, Z., Lan, R., Liu, Y., Ward, D. C., Quan, J., Ye, T., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0896 · Cited by 229 · see citing works

A SIRT1-LSD1 Corepressor Complex Regulates Notch Target Gene Expression and Development

Mulligan, P., Yang, F., Stefano, L. D., Ji, J., Ouyang, J., Nishikawa, J. L., Toiber, D., Kulkarni, M., Wang, Q., Najafi-Shoushtari, S. H., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.04.020 · Cited by 211 · see citing works

The histone LSD1 demethylase in stemness and cancer transcription programs

Amente, S., Lania, L., & Majello, B. (2013) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2013.05.002 · Cited by 206 · see citing works

Structural insights into histone lysine demethylation

Hou, H., & Yu, H. (2010) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2010.09.006 · Cited by 179 · see citing works

LSD1-mediated demethylation of histone H3 lysine 4 triggers Myc-induced transcription

Amente, S., Bertoni, A., Morano, A., Lania, L., Avvedimento, E. V., & Majello, B. (2010) · Oncogene · doi:10.1038/onc.2010.120 · Cited by 171 · see citing works

Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma

Sankar, S., Bell, R. N., Stephens, B. J., Zhuo, R., Sharma, S., Bearss, D. J., & Lessnick, S. L. (2012) · Oncogene · doi:10.1038/onc.2012.525 · Cited by 166 · see citing works

Human acute leukemia cells injected in NOD/LtSz‐<i>scid/IL‐2Rγ</i> null mice generate a faster and more efficient disease compared to other NOD/<i>scid</i>‐related strains

Agliano, A., Martin‐Padura, I., Mancuso, P., Marighetti, P., Rabascio, C., Pruneri, G., Shultz, L. D., & Bertolini, F. (2008) · International Journal of Cancer · doi:10.1002/ijc.23772 · Cited by 163 · see citing works

Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors

Singh, M. M., Manton, C. A., Bhat, K., Tsai, W.-W., Aldape, K., Barton, M. C., & Chandra, J. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor049 · Cited by 150 · see citing works

LSD1 and the chemistry of histone demethylation

Culhane, J. C., & Cole, P. A. (2007) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2007.07.014 · Cited by 143 · see citing works

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies

DeAngelo, D. J., Spencer, A. G., Bhalla, K. N., Prince, H. M., Fischer, T., Kindler, T., Giles, F. J., Scott, J. W., Parker, K., Liu, A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.38 · Cited by 140 · see citing works

Erratum: Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma

Sankar, S., Bell, R. N., Stephens, B. J., Zhuo, R., Sharma, S., Bearss, D. J., & Lessnick, S. L. (2016) · Oncogene · doi:10.1038/onc.2016.142 · Cited by 138 · see citing works

A Highly Specific Mechanism of Histone H3-K4 Recognition by Histone Demethylase LSD1

Forneris, F., Binda, C., Dall'Aglio, A., Fraaije, M. W., Battaglioli, E., & Mattevi, A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m607411200 · Cited by 135 · see citing works

Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells

Huang, Y., Vasilatos, S. N., Boric, L., Shaw, P. G., & Davidson, N. E. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1480-8 · Cited by 132 · see citing works

Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1

Balusu, R., Fiskus, W. C., Rao, R., Chong, D. G., Nalluri, S., Mudunuru, U., Ma, H., Chen, L., Venkannagari, S., Ha, K., et al. (2011) · Blood · doi:10.1182/blood-2010-09-309674 · Cited by 131 · see citing works

A robust xenotransplantation model for acute myeloid leukemia

Sanchez, P. V., Perry, R. L., Sarry, J., Perl, A. E., Murphy, K. M., Swider, C. R., Bagg, A., Choi, J. K., Biegel, J. A., Danet-Desnoyers, G. A., et al. (2009) · Leukemia · doi:10.1038/leu.2009.143 · Cited by 127 · see citing works

Intrinsic and Extrinsic Apoptotic Pathway Signaling as Determinants of Histone Deacetylase Inhibitor Antitumor Activity

Matthews, G. M., Newbold, A., & Johnstone, R. W. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-394387-3.00005-7 · Cited by 120 · see citing works

LSD1-mediated epigenetic modification is required for TAL1 function and hematopoiesis

Hu, X., Li, X., Valverde, K., Fu, X., Noguchi, C. T., Qiu, Y., & Huang, S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900437106 · Cited by 117 · see citing works

Histone Deacetylase Inhibitors Stimulate Histone H3 Lysine 4 Methylation in Part Via Transcriptional Repression of Histone H3 Lysine 4 Demethylases

Huang, P.-H., Chen, C.-H., Chou, C.-C., Sargeant, A. M., Kulp, S. K., Teng, C., Byrd, J. C., & Chen, C. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.067702 · Cited by 110 · see citing works

Dual PI3K/AKT/mTOR Inhibitor BEZ235 Synergistically Enhances the Activity of JAK2 Inhibitor against Cultured and Primary Human Myeloproliferative Neoplasm Cells

Fiskus, W. C., Verstovšek, S., Manshouri, T., Smith, J. E., Peth, K., Abhyankar, S., McGuirk, J. P., & Bhalla, K. N. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0862 · Cited by 106 · see citing works

Overexpression of lysine specific demethylase 1 predicts worse prognosis in primary hepatocellular carcinoma patients

Zhao, Z.-K. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i45.6651 · Cited by 83 · see citing works

Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis

DeAngelo, D. J., Mesa, R. A., Fiskus, W. C., Tefferi, A., Paley, C. S., Wadleigh, M., Ritchie, E. K., Snyder, D., Begna, K. H., Ganguly, S., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12384 · Cited by 73 · see citing works

Dynamic interaction between TAL1 oncoprotein and LSD1 regulates TAL1 function in hematopoiesis and leukemogenesis

Li, Y., Deng, C., Hu, X., Patel, B., Fu, X., Qiu, Y., Brand, M., Zhao, K., & Huang, S. (2012) · Oncogene · doi:10.1038/onc.2012.8 · Cited by 67 · see citing works

CD86 expression as a surrogate cellular biomarker for pharmacological inhibition of the histone demethylase lysine-specific demethylase 1

Lynch, J. T., Cockerill, M. J., Hitchin, J. R., Wiseman, D. H., & Somervaille, T. C. P. (2013) · Analytical Biochemistry · doi:10.1016/j.ab.2013.07.032 · Cited by 58 · see citing works

Targeting p27Kip1protein: its relevance in the therapy of human cancer

Borriello, A., Bencivenga, D., Criscuolo, M., Caldarelli, I., Cucciolla, V., Tramontano, A., Borgia, A., Spina, A., Oliva, A., Naviglio, S., et al. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.561318 · Cited by 56 · see citing works

Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells

Fiskus, W. C., Rao, R., Balusu, R., Ganguly, S., Tao, J., Sotomayor, E. M., Mudunuru, U., Smith, J. E., Hembruff, S. L., Atadja, P. W., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0873 · Cited by 49 · see citing works

Novel treatments in acute myeloid leukemia.

Ravandi, F. (2011) · PubMed · Cited by 1 · see citing works

Epigenetic Determinants of CancerPreprint

Baylin, S. B., & Jones, P. A. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019505 · Cited by 1,363 · see citing works

HDACs and HDAC Inhibitors in Cancer Development and TherapyPreprint

Li, Y., & Seto, E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026831 · Cited by 1,309 · see citing works

Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials

Cheng, Y., He, C., Wang, M., Ma, X., Mo, F., Yang, S., Han, J., & Wei, X. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0095-0 · Cited by 1,097 · see citing works

LSD1/KDM1A inhibitors in clinical trials: advances and prospects

Fang, Y., Liao, G., & Yu, B. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0811-9 · Cited by 453 · see citing works

Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy

Morera, L., Lübbert, M., & Jung, M. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0223-4 · Cited by 396 · see citing works

Critical roles of non-histone protein lysine methylation in human tumorigenesis

Hamamoto, R., Saloura, V., & Nakamura, Y. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3884 · Cited by 376 · see citing works

Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Bose, P., Vachhani, P. J., & Cortes, J. E. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0456-2 · Cited by 239 · see citing works

LSD1 activates a lethal prostate cancer gene network independently of its demethylase function

Sehrawat, A., Gao, L., Wang, Y., Bankhead, A., McWeeney, S. K., King, C. J., Schwartzman, J. A., Urrutia, J. A., Bisson, W. H., Coleman, D. J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1719168115 · Cited by 226 · see citing works

HDAC Inhibitors in Acute Myeloid Leukemia

José‐Eneriz, E. S., Gimenez-Camino, N., Agirre, X., & Prósper, F. (2019) · Cancers · doi:10.3390/cancers11111794 · Cited by 228 · see citing works

Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia

Maiqués-Díaz, A., Spencer, G. J., Lynch, J. T., Ciceri, F., Williams, E. L., Amaral, F. M. R., Wiseman, D. H., Harris, W. J., Li, Y., Sahoo, S., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.012 · Cited by 208 · see citing works

LSD1: Biologic Roles and Therapeutic Targeting

Maiqués-Díaz, A., & Somervaille, T. C. P. (2016) · Epigenomics · doi:10.2217/epi-2016-0009 · Cited by 207 · see citing works

A Systematic Review of Histone Lysine‐Specific Demethylase 1 and Its Inhibitors

Zheng, Y., Ma, J., Wang, Z., Li, J., Jiang, B., Zhou, W., Shi, X., Wang, X., Zhao, W., & Liu, H. (2015) · Medicinal Research Reviews · doi:10.1002/med.21350 · Cited by 189 · see citing works

Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG

Anastas, J. N., Zee, B. M., Kalin, J. H., Kim, M., Guo, R., Alexandrescu, S., Blanco, M. A., Giera, S., Gillespie, S. M., Das, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.005 · Cited by 188 · see citing works

Targeting histone lysine methylation in cancer

McGrath, J. P., & Trojer, P. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.01.002 · Cited by 188 · see citing works

MYC—Master Regulator of the Cancer Epigenome and Transcriptome

Poole, C. J., & van Riggelen, J. (2017) · Genes · doi:10.3390/genes8050142 · Cited by 177 · see citing works

Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends

Nepali, K., & Liou, J. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00721-x · Cited by 185 · see citing works

Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives

Song, Y., Wu, F., & Wu, J. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0279-9 · Cited by 151 · see citing works

Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs

Brien, G. L., Valerio, D. G., & Armstrong, S. A. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.007 · Cited by 146 · see citing works

Reversible Inhibitors of LSD1 as Therapeutic Agents in Acute Myeloid Leukemia: Clinical Significance and Progress to Date

Mould, D. P., McGonagle, A. E., Wiseman, D. H., Williams, E. L., & Jordan, A. M. (2014) · Medicinal Research Reviews · doi:10.1002/med.21334 · Cited by 138 · see citing works

A Comprehensive Review of Lysine-Specific Demethylase 1 and its Roles in Cancer

Hosseini, A., & Minucci, S. (2017) · Epigenomics · doi:10.2217/epi-2017-0022 · Cited by 137 · see citing works

Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma

Huang, M., Chen, C. Y., Geng, J., Han, D. H., Wang, T., Xie, T., Wang, L., Wang, Y., Wang, C., Lei, Z., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.03.038 · Cited by 134 · see citing works

Advances Toward Lsd1 Inhibitors for Cancer Therapy

Fu, X., Zhang, P., & Yu, B. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0068 · Cited by 133 · see citing works

Pharmacological Inhibition of LSD1 for Cancer Treatment

Yang, G., Lei, P.-M., Wong, S.-Y., Ma, D., & Leung, C. (2018) · Molecules · doi:10.3390/molecules23123194 · Cited by 129 · see citing works

Histone Demethylases and Their Roles in Cancer Epigenetics

D’Oto, A., Tian, Q., Davidoff, A. M., & Yang, J. (2016) · Journal of medical oncology and therapeutics · doi:10.35841/medical-oncology.1.2.34-40 · Cited by 127 · see citing works

Natural products as LSD1 inhibitors for cancer therapy

Fang, Y., Yang, C., Yu, Z., Li, X., Mu, Q., Liao, G., & Yu, B. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.06.007 · Cited by 124 · see citing works

Biological roles of LSD1 beyond its demethylase activity

Gu, F., Lin, Y., Wang, Z., Wu, X., Ye, Z., Wang, Y., & Lan, H. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03489-9 · Cited by 121 · see citing works

Advances in the development of histone lysine demethylase inhibitors

Maes, T., Carceller, E., Salas‐Salvadó, J., Ortega, A., & Buesa, C. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.05.009 · Cited by 121 · see citing works

The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia

Baker, A., Gregory, G. P., Verbrugge, I., Kats, L. M., Hilton, J. J., Vidacs, E., Lee, E. M., Lock, R. B., Zuber, J. A., Shortt, J., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1070 · Cited by 117 · see citing works

LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML

Cusan, M., Cai, S. F., Mohammad, H. P., Krivtsov, A. V., Chramiec, A. G., Loizou, E., Witkin, M. D., Smitheman, K. N., Tenen, D. G., Ye, M., et al. (2018) · Blood · doi:10.1182/blood-2017-09-807024 · Cited by 117 · see citing works

A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells

Ishikawa, Y., Gamo, K., Yabuki, M., Takagi, S., Toyoshima, K., Nakayama, K., Nakayama, A., Morimoto, M., Miyashita, H., Dairiki, R., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0471 · Cited by 92 · see citing works

Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes

McGrath, J. P., Williamson, K. E., Balasubramanian, S., Odate, S., Arora, S., Hatton, C., Edwards, T. M., O’Brien, T., Magnuson, S. R., Stokoe, D., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2333 · Cited by 107 · see citing works

Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia

Li, Y., Zhang, M., Sheng, M., Zhang, P., Chen, Z., Xing, W., Bai, J., Cheng, T., Yang, F., & Zhou, Y. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2631-7 · Cited by 107 · see citing works

A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy

Wass, M., Göllner, S., Besenbeck, B., Schlenk, R. F., Mundmann, P., Göthert, J. R., Noppeney, R., Schliemann, C., Mikesch, J., Lenz, G., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0892-z · Cited by 106 · see citing works

Targeting the canonical Wnt/β‐catenin pathway in hematological malignancies

Ashihara, E., Takada, T., & Maekawa, T. (2015) · Cancer Science · doi:10.1111/cas.12655 · Cited by 107 · see citing works

Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia

Feng, Z., Yao, Y., Zhou, C., Chen, F., Wu, F., Wei, L., Liu, W., Dong, S., Redell, M. S., Mo, Q., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0252-7 · Cited by 105 · see citing works

LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression

Liang, Y., Ahmed, M., Guo, H., Soares, F., Hua, J. T., Gao, S., Lu, C., Poon, C., Han, W., Langstein, J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0496 · Cited by 100 · see citing works

Novel KDM1A inhibitors induce differentiation and apoptosis of glioma stem cells via unfolded protein response pathway

Sareddy, G. R., Viswanadhapalli, S., Surapaneni, P., Suzuki, T., Brenner, A. J., & Vadlamudi, R. (2016) · Oncogene · doi:10.1038/onc.2016.395 · Cited by 98 · see citing works

Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells

Fiskus, W. C., Sharma, S., Saha, S., Shah, B. N., Devaraj, S. G. T., Sun, B., Horrigan, S. K., Leveque, C. M., Zu, Y., Iyer, S. P., et al. (2014) · Leukemia · doi:10.1038/leu.2014.340 · Cited by 98 · see citing works

Pharmacological inhibition of dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid leukemia cells

Wu, D., Wang, W., Chen, W., Lian, F., Lang, L., Huang, Y., Xu, Y., Zhang, N., Chen, Y., Liu, M., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.188185 · Cited by 97 · see citing works

Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment

Duan, Y., Ma, Y., Qin, W., Ding, L., Zheng, Y., Zhu, Y., Zhai, X.-Y., Yang, J. C., Ma, C.-Y., & Guan, Y. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.038 · Cited by 96 · see citing works

Lysine-specific demethylase LSD1 regulates autophagy in neuroblastoma through SESN2-dependent pathway

Ambrosio, S., Saccà, C. D., Amente, S., Paladino, S., Lania, L., & Majello, B. (2017) · Oncogene · doi:10.1038/onc.2017.267 · Cited by 88 · see citing works

Lysine-Specific Demethylase 1A as a Promising Target in Acute Myeloid Leukemia

Magliulo, D., Bernardi, R., & Messina, S. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00255 · Cited by 88 · see citing works

Epigenetic therapy combinations in acute myeloid leukemia: what are the options?

Bewersdorf, J. P., Shallis, R. M., Stahl, M. F., & Zeidan, A. M. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620718816698 · Cited by 85 · see citing works

Epigenetic Deregulation of Apoptosis in Cancers

Ozyerli‐Goknar, E., & Onder, T. B. (2021) · Cancers · doi:10.3390/cancers13133210 · Cited by 89 · see citing works

KDM1 Histone Lysine Demethylases as Targets for Treatments of Oncological and Neurodegenerative Disease

Maes, T., Mascaró, C., Ortega, A., Lunardi, S., Ciceri, F., Somervaille, T. C. P., & Buesa, C. (2015) · Epigenomics · doi:10.2217/epi.15.9 · Cited by 86 · see citing works

Targeting LSD1 for acute myeloid leukemia (AML) treatment

Zhang, S., Liu, M., Yao, Y., Yu, B., & Liu, H. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105335 · Cited by 85 · see citing works

Digging deep into “dirty” drugs – modulation of the methylation machinery

Pleyer, L., & Greil, R. (2015) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.995379 · Cited by 84 · see citing works

Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer

Lin, K., Rutter, J. C., Xie, A., Pardieu, B., Winn, E. T., Bello, R. D., Forget, A., Itzykson, R., Ahn, Y.-R., Dai, Z., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0590-9 · Cited by 84 · see citing works

TCPs: Privileged Scaffolds for Identifying Potent LSD1 Inhibitors for Cancer Therapy

Zheng, Y., Yu, B., Chen, Z., Liu, Y., & Liu, H. (2016) · Epigenomics · doi:10.2217/epi-2015-0002 · Cited by 84 · see citing works

Development of the triazole-fused pyrimidine derivatives as highly potent and reversible inhibitors of histone lysine specific demethylase 1 (LSD1/KDM1A)

Li, Z., Ding, L., Li, Z., Wang, Z., Suo, F., Shen, D., Zhao, T., Sun, X., Wang, J., Liu, Y., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.01.001 · Cited by 83 · see citing works

Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma

Singh, M. M., Johnson, B., Venkatarayan, A., Flores, E. R., Zhang, J., Su, X., Barton, M. C., Lang, F., & Chandra, J. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov041 · Cited by 83 · see citing works

KRT6A Promotes Lung Cancer Cell Growth and Invasion Through MYC-Regulated Pentose Phosphate Pathway

Che, D., Wang, M., Sun, J., Li, B., Xu, T., Lu, Y., Pan, H., Lu, Z., & Gu, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.694071 · Cited by 82 · see citing works

Efficient combinatorial targeting of RNA transcripts in single cells with Cas13 RNA Perturb-seq

Wessels, H.-H., Méndez-Mancilla, A., Hao, Y., Papalexi, E., Mauck, W. M., Lu, L., Morris, J. A., Mimitou, E. P., Smibert, P., Sanjana, N. E., et al. (2023) · Nature Methods · doi:10.1038/s41592-022-01705-x · Cited by 79 · see citing works

KDM1A microenvironment, its oncogenic potential, and therapeutic significance

Ismail, T., Lee, H.-K., Kim, C., Kwon, T., Park, T. J., & Lee, H. (2018) · Epigenetics & Chromatin · doi:10.1186/s13072-018-0203-3 · Cited by 77 · see citing works

Epigenetic regulation of endothelial‐cell‐mediated vascular repair

Fraineau, S., Palii, C. G., Allan, D., & Brand, M. (2014) · FEBS Journal · doi:10.1111/febs.13183 · Cited by 76 · see citing works

Histone Lysine Demethylase InhibitorsPreprint

Jambhekar, A., Anastas, J. N., & Shi, Y. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026484 · Cited by 76 · see citing works

Emerging approaches for histone deacetylase inhibitor drug discovery

Zwergel, C., Valente, S., Jacob, C., & Mai, A. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1038236 · Cited by 75 · see citing works

A novel LSD1 inhibitor NCD38 ameliorates MDS-related leukemia with complex karyotype by attenuating leukemia programs via activating super-enhancers

Sugino, N., Kawahara, M., Tatsumi, G., Kanai, A., Matsui, H., Yamamoto, R., Nagai, Y., Fujii, S., Shimazu, Y., Hishizawa, M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.59 · Cited by 74 · see citing works

LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML

Barth, J., Abou‐El‐Ardat, K., Dalic, D., Kurrle, N., Maier, A., Mohr, S., Schütte, J., Vaßen, L., Greve, G., Schulz‐Fincke, J., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0375-7 · Cited by 73 · see citing works

Similarity in gene-regulatory networks suggests that cancer cells share characteristics of embryonic neural cells

Zhang, Z., Lei, A., Xu, L., Chen, L., Chen, Y., Zhang, X., Gao, Y. H., Yang, X., Zhang, M., & Cao, Y. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.785865 · Cited by 71 · see citing works

The role of targeted therapy in the management of patients with AML

Perl, A. E. (2017) · Hematology · doi:10.1182/asheducation-2017.1.54 · Cited by 70 · see citing works

Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting

Theisen, E. R., Pishas, K. I., Saund, R. S., & Lessnick, S. L. (2016) · Oncotarget · doi:10.18632/oncotarget.7124 · Cited by 69 · see citing works

Direct and Indirect Targeting of HOXA9 Transcription Factor in Acute Myeloid Leukemia

Lambert, M., Alioui, M., Jambon, S., Depauw, S., van Seuningen, I., & David-Cordonnier, M. (2019) · Cancers · doi:10.3390/cancers11060837 · Cited by 58 · see citing works

Role of Lysine‐Specific Demethylase 1 in Metabolically Integrating Osteoclast Differentiation and Inflammatory Bone Resorption Through Hypoxia‐Inducible Factor 1α and E2F1

Doi, K., Murata, K., Ito, S., Suzuki, A., Terao, C. C., Ishie, S., Umemoto, A., Murotani, Y., Nishitani, K., Yoshitomi, H., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42074 · Cited by 70 · see citing works

KDM1 class flavin‐dependent protein lysine demethylases

Burg, J. M., Link, J. E., Morgan, B. S., Heller, F. J., Hargrove, A. E., & McCafferty, D. G. (2015) · Biopolymers · doi:10.1002/bip.22643 · Cited by 69 · see citing works

Codelivery of doxorubicin and triptolide with reduction-sensitive lipid–polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment

Wu, B., Lu, S., Zhang, L.-J., Zhuo, R., Xu, H., & Huang, S. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s131235 · Cited by 69 · see citing works

Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome

Raynal, N. J. ‐., Costa, E. M. D., Lee, J. T., Gharibyan, V., Ahmed, S., Zhang, H., Sato, T., Malouf, G. G., & Issa, J. J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0588 · Cited by 67 · see citing works

Hypoxia Promotes Resistance to EGFR Inhibition in NSCLC Cells via the Histone Demethylases, LSD1 and PLU-1

Lü, Y., Liu, Y., Oeck, S., & Glazer, P. M. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0637 · Cited by 68 · see citing works

The role of targeted therapy in the management of patients with AML

Perl, A. E. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017009829 · Cited by 66 · see citing works

Pharmacoepigenetics and Toxicoepigenetics: Novel Mechanistic Insights and Therapeutic Opportunities

Lauschke, V. M., Barragán, I., & Ingelman‐Sundberg, M. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-053021 · Cited by 62 · see citing works

Histone methylation in DNA repair and clinical practice: new findings during the past 5-years

Wei, S., Li, C., Yin, Z., Wen, J., Meng, H., Xue, L., & Wang, J. (2018) · Journal of Cancer · doi:10.7150/jca.23427 · Cited by 62 · see citing works

Discovery of resveratrol derivatives as novel LSD1 inhibitors: Design, synthesis and their biological evaluation

Duan, Y., Guan, Y., Zhai, X.-Y., Ding, L., Qin, W., Shen, D., Liu, X., Sun, X., Zheng, Y., & Liu, H. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.11.035 · Cited by 61 · see citing works

Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia

Togasaki, E., Takeda, J., Yoshida, K., Shiozawa, Y., Takeuchi, M., Oshima, M., Saraya, A., Iwama, A., Yokote, K., Sakaida, E., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.36 · Cited by 61 · see citing works

Epigenetic Regulators in the Development, Maintenance, and Therapeutic Targeting of Acute Myeloid Leukemia

Sun, Y., Chen, B.-R., & Deshpande, A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00041 · Cited by 52 · see citing works

Current Advances in Coptidis Rhizoma for Gastrointestinal and Other Cancers

He, L., Zhong, Z., Chen, M., Liang, Q., Wang, Y., & Tan, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.775084 · Cited by 57 · see citing works

Structural insight into inhibitors of flavin adenine dinucleotide-dependent lysine demethylases

Niwa, H., & Umehara, T. (2017) · Epigenetics · doi:10.1080/15592294.2017.1290032 · Cited by 57 · see citing works

Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells

Haydn, T., Metzger, E., Schüle, R., & Fulda, S. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.239 · Cited by 57 · see citing works

LSD1 inhibition suppresses the growth of clear cell renal cell carcinoma via upregulating P21 signaling

Zhu, L., Wang, J., Kong, W., Huang, J., Dong, B., Huang, Y., Xue, W., & Zhang, J. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.10.006 · Cited by 57 · see citing works

Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer

Duan, Y., Jin, L., Ren, H.-M., Zhang, S., Liu, Y.-J., Xu, Y., He, Z., Song, Y., Yuan, H., Chen, S.-H., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113453 · Cited by 55 · see citing works

Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies

Tayari, M. M., Santos, H. G. D., Kwon, D., Bradley, T., Thomassen, A., Chen, C. Y., Dinh, Y. T., Perez, A., Zelent, A., Morey, L., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4054 · Cited by 53 · see citing works

SUV39H2 methylates and stabilizes LSD1 by inhibiting polyubiquitination in human cancer cells

Piao, L., Suzuki, T., Dohmae, N., Nakamura, Y., & Hamamoto, R. (2015) · Oncotarget · doi:10.18632/oncotarget.4760 · Cited by 54 · see citing works

Stepwise assembly of functional C‐terminal REST/NRSF transcriptional repressor complexes as a drug target

Inui, K., Zhao, Z., Yuan, J., Jayaprakash, S., Le, L. T. M., Drakulić, S., Sander, B. O., & Golas, M. M. (2017) · Protein Science · doi:10.1002/pro.3142 · Cited by 54 · see citing works

Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia

Gallipoli, P., Giotopoulos, G., & Huntly, B. J. P. (2015) · Therapeutic Advances in Hematology · doi:10.1177/2040620715577614 · Cited by 52 · see citing works

Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes

Stahl, M. F., Gore, S. D., Vey, N., & Prébet, T. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1146251 · Cited by 52 · see citing works

FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer

Wang, Z., Townley, S. L., Zhang, S., Liu, M., Li, M., Labaf, M., Patalano, S. C., Venkataramani, K., Siegfried, K. R., Macoska, J. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49234-9 · Cited by 51 · see citing works

Epigenetic regulation of epithelial to mesenchymal transition by the Lysine-specific demethylase LSD1/KDM1A

Ambrosio, S., Saccà, C. D., & Majello, B. (2017) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2017.07.001 · Cited by 52 · see citing works

Lysine-specific demethylase 1 (LSD1) destabilizes p62 and inhibits autophagy in gynecologic malignancies

Chao, A., Lin, C., Chao, A., Tsai, C.-L., Chen, M., Lee, L., Chang, T., Wang, T., Lai, C., & Wang, H. (2017) · Oncotarget · doi:10.18632/oncotarget.20158 · Cited by 51 · see citing works

Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy

Castelli, G., Pelosi, E., & Testa, U. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s145971 · Cited by 51 · see citing works

Drugging Chromatin in Cancer: Recent Advances and Novel Approaches

Cai, S. F., Chen, C.-W. D., & Armstrong, S. A. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.042 · Cited by 50 · see citing works

Medicinal Chemistry Insights in the Discovery of Novel LSD1 Inhibitors

Wang, X., Huang, B., Suzuki, T., Liu, X., & Zhan, P. (2015) · Epigenomics · doi:10.2217/epi.15.86 · Cited by 50 · see citing works

LSD1 inhibitors: a patent review (2010-2015)

Stazi, G., Zwergel, C., Valente, S., & Mai, A. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2016.1165209 · Cited by 50 · see citing works

Natural protoberberine alkaloids, identified as potent selective LSD1 inhibitors, induce AML cell differentiation

Li, Z., Suo, F., Guo, Y.-J., Cheng, H.-F., Niu, S.-H., Shen, D., Zhao, L., Liu, Z., Maa, M., Yu, B., et al. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103648 · Cited by 49 · see citing works

Epigenetics: A primer for clinicians

Paluch, B. E., Naqash, A. R., Brumberger, Z. L., Nemeth, M. J., & Griffiths, E. A. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.02.002 · Cited by 49 · see citing works

Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells

Gupta, S. V., Weston, A., Bearss, J. J., Thode, T. G., Neiss, A., Soldi, R., & Sharma, S. (2016) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2016.21 · Cited by 49 · see citing works

Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects

Gambacorta, V., Gnani, D., Vago, L., & Micco, R. D. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00207 · Cited by 48 · see citing works

Epigenetic regulators and their impact on therapy in acute myeloid leukemia

Pastore, F., & Levine, R. (2016) · Haematologica · doi:10.3324/haematol.2015.140822 · Cited by 50 · see citing works

MEN1 deficiency leads to neuroendocrine differentiation of lung cancer and disrupts the DNA damage response

Qiu, H., Jin, B., Wang, Z., Xu, B., Zheng, Q., Zhang, L., Zhu, L.-Y., Shi, S., Yuan, J.-B., Lin, X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14614-4 · Cited by 48 · see citing works

Changing the Paradigms of Treatment in Peripheral T-cell Lymphoma: From Biology to Clinical Practice

O’Connor, O. A., Bhagat, G., Ganapathi, K. A., Pedersen, M. B., d’Amore, F., Radeski, D., & Bates, S. E. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2020 · Cited by 47 · see citing works

Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo

Wen, S., Wang, J., Liu, P., Li, Y., Lu, W., Hu, Y., Liu, J., He, Z., & Huang, P. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.10.015 · Cited by 46 · see citing works

Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines

Welch, D. L., Kahen, E., Fridley, B. L., Brohl, A. S., Cubitt, C. L., & Reed, D. R. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222228 · Cited by 46 · see citing works

Pre-Clinical Efficacy of Combined Therapy with LSD1 Antagonist SP-2509 and Pan-Histone Deacetylase Inhibitor Against AML Blast Progenitor Cells

Fiskus, W. C., Sharma, S., Abhyankar, S., McGuirk, J. P., Bearss, D. J., & Bhalla, K. N. (2012) · Blood · doi:10.1182/blood.v120.21.868.868 · Cited by 8 · see citing works

Combined targeting of LSD1 (KDM1A) and histone deacetylases exerts superior efficacy against human AML.

Fiskus, W. C., Sharma, S., Rao, R., Balusu, R., Venkannagari, S., Ganguly, S., Bearss, D. J., & Bhalla, K. N. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.10549

Abstract 1043: Combined targeting of chromatin modifying enzymes LSD1, histone deacetylases (HDACs) and EZH2 has superior efficacy against human acute myeloid leukemia cells.

Fiskus, W. C., Sharma, S., Rao, R., Balusu, R., Venkannagari, S., Hembruff, S. L., Abhyankar, S., McGuirk, J. P., Aljitawi, O. S., Ganguly, S., et al. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-1043

Inhibition Of LSD1 As a Therapeutic Strategy For The Treatment Of Acute Myeloid Leukemia

Kruger, R. G., Mohammad, H. P., Smitheman, K. N., Cusan, M., Liu, Y., Pappalardi, M. B., Federowicz, K., Aller, G. V., Kasparec, J., Tian, X., et al. (2013) · Blood · doi:10.1182/blood.v122.21.3964.3964 · Cited by 28 · see citing works

Synergistic Pre-Clinical Activity of Targeted Inhibition of KDM1A and BET Proteins Against Human AML Blast Progenitor Cells

Fiskus, W. C., Mill, C. P., Soldi, R., Han, R., Saenz, D. T., Nowak, A. J., Sun, B., Saenz, D. N., Dinardo, C. D., Borthakur, G. M., et al. (2018) · Blood · doi:10.1182/blood-2018-99-114198 · Cited by 8 · see citing works